aid: bipar-sciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/bipar-sciences.png
name: Bipar Sciences
description: 'BiPar Sciences was a Brisbane, California biopharmaceutical company developing
  a tumor-selective class of PARP (poly ADP-ribose polymerase) inhibitors for cancer therapy.
  Its lead candidate, BSI-201 (iniparib), was in mid-stage trials for advanced breast, ovarian,
  and other tumors. Backed by Canaan Partners, Vulcan Capital, PolyTechnos, Asset Management
  Company, and Quantum Technology Partners, BiPar was acquired by Sanofi-Aventis for roughly
  $500 million in April 2009 and no longer operates as an independent company. It was surfaced
  as a Canaan Partners portfolio company and added to the API Evangelist network as a stub;
  enrichment finds no public developer or API surface.'
url: https://raw.githubusercontent.com/api-evangelist/bipar-sciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Oncology
- Pharmaceuticals
- PARP Inhibitors
- Clinical Trials
- Acquired
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence